ZGEN's rhThrombin meets Phase III endpoint

ZymoGenetics (ZGEN) said rhThrombin met the primary endpoint in a Phase III trial to control blood loss during surgery. The endpoint in the double-blind U.S. trial in 411 patients was non-inferior inc...